The usual key to the quarterly earnings is the amount of cash and cash equivalents available to sustain the organization through the new few Q’s or “runway”.
What matters beyond the spending … are the significant milestones and catalysts in furthering clinical development and trials… and if they have the cash to advance their vision and focus. I still believe companies … strive to fulfill the “sows ear to a silk purse” promise to … unlock … any future value to shareholders.
November 28, 2020
RegMed/Cell and Gene Therapy Earnings Scorecard Q3/20 LPS Results
April 11, 2020
Regenerative Medicine Earnings Scorecard - Q4 & FY19
November 3, 2019
RegMed Investors’ (RMi): Ready, aim, clear the estimates and forecast firing range, earnings release are set to light-up and down size the sector
November 23, 2018
Regenerative Medicine Earnings Scorecard - Q3/18 - to date
November 9, 2018
Quarterly (Q3) results special: ADVM, HSGX, BTX, AGTC, ONVO, XON, BLFS, CLBS, PSTI, SGMO, STML and BSTG
November 8, 2018
Quarterly (Q3) results special: ALNY, CRSP, EDIT, OSIR, RGNX, SAGE, VYGR, VSTM and EDIT
November 7, 2018
Quarterly (Q3) results special: ATHX, BOLD, BLCM and GBT
November 6, 2018
Quarterly (Q3) results special: IONS, ONCE, QURE and VCEL
September 11, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
June 2, 2018
Regenerative Medicine Earnings Scorecard - Q1/18 - to date
March 10, 2018
Regenerative Medicine Earnings Scorecard - Q4 and FY17 - to date
November 3, 2017
Regenerative Medicine Earnings Scorecard - Q3/2017 - to date
August 9, 2017
Regenerative Medicine Earnings Scorecard - Q2/2017 - to date
May 5, 2017
Regenerative Medicine Earnings Scorecard - Q1/2017 - to date
March 10, 2017
Regenerative Medicine Earnings Scorecard - Q4/2016 - to date
November 2, 2016
Regenerative Medicine Earnings Scorecard - Q3/2016 - to date
August 4, 2016
Regenerative Medicine Earnings Scorecard - Q2/2016 - to date
May 26, 2016
Regenerative Medicine Earnings Scorecard - Q1/2016 - to date
February 9, 2016
Regenerative Medicine Earnings Scorecard - Q4/2015
April 13, 2015
BioLife Solutions (BLFS) Preliminary Q1/15 revenue of $1.5 M
February 26, 2015
MiMedx (MDXG) Record ‘14 revenue and first operating profit, UP +0.47 or +4.93% in pre-market
February 18, 2015
Pluristem (PSTI) Q4/14 Earnings: NET LOSS UP +4.9%, LPS FLAT
February 17, 2015
Cesca (KOOL) Q4/14 Earnings: LOSS UP +25%, LPS UP +27%
February 17, 2015
Organovo (NYSEMKT: ONVO) Q1/15 Earnings: LOSS DOWN -21.4%, LPS DOWN -26.4%
January 12, 2015
BioLife Solutions (BLFS) reports preliminary revenue for Q4’14 and FY’14 - BUY
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2020 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.